New investigations into retatrutide, a dual agonist for GLP-1 and GIP receptors, are showing significant outcomes in managing excess mass and related non-insulin-dependent condition. Animal data suggest a distinct https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/